Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An emulation of a pragmatic trial in COHERE

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Outcome of dialysis-requiring acute kidney injury in patients with infective endocarditis: A nationwide study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Altered Immune Reconstitution in Allogeneic Stem Cell Transplant Recipients With Human Immunodeficiency Virus (HIV)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Varicella Zoster Virus encephalitis in Denmark from 2015 to 2019- A nationwide prospective cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Causes and outcomes of hospitalizations among people living with HIV in Georgia's referral institution, 2012-2017

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Healthcare delivery for HIV-positive people with tuberculosis in Europe

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Behandling af indlæggelseskrævende COVID-19

    Publikation: Bidrag til tidsskriftReviewpeer review

  • A Atkinson
  • M Zwahlen
  • D Barger
  • A d'Arminio Monforte
  • S De Wit
  • J Ghosn
  • E Girardi
  • V Svedhem-Johansson
  • P Morlat
  • C Mussini
  • A Noguera-Julian
  • C Stephan
  • G Touloumi
  • O Kirk
  • A Mocroft
  • P Reiss
  • J M Miro
  • J R Carpenter
  • H Furrer
  • Opportunistic Infections Project Working Group of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord
Vis graf over relationer

BACKGROUND: Using data from the COHERE collaboration, we investigated whether primary prophylaxis for pneumocystis pneumonia (PcP) might be withheld in all patients on antiretroviral therapy (ART) with suppressed plasma human immunodeficiency virus (HIV) RNA (≤400 copies/mL), irrespective of CD4 count.

METHODS: We implemented an established causal inference approach whereby observational data are used to emulate a randomized trial. Patients taking PcP prophylaxis were eligible for the emulated trial if their CD4 count was ≤200 cells/µL in line with existing recommendations. We compared the following 2 strategies for stopping prophylaxis: (1) when CD4 count was >200 cells/µL for >3 months or (2) when the patient was virologically suppressed (2 consecutive HIV RNA ≤400 copies/mL). Patients were artificially censored if they did not comply with these stopping rules. We estimated the risk of primary PcP in patients on ART, using the hazard ratio (HR) to compare the stopping strategies by fitting a pooled logistic model, including inverse probability weights to adjust for the selection bias introduced by the artificial censoring.

RESULTS: A total of 4813 patients (10 324 person-years) complied with eligibility conditions for the emulated trial. With primary PcP diagnosis as an endpoint, the adjusted HR (aHR) indicated a slightly lower, but not statistically significant, different risk for the strategy based on viral suppression alone compared with the existing guidelines (aHR, .8; 95% confidence interval, .6-1.1; P = .2).

CONCLUSIONS: This study suggests that primary PcP prophylaxis might be safely withheld in confirmed virologically suppressed patients on ART, regardless of their CD4 count.

TidsskriftClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Udgave nummer2
Sider (fra-til)195-202
Antal sider8
StatusUdgivet - 15 jul. 2021

Bibliografisk note

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.

ID: 60545895